FindTrial
Sign In

Proton Pump Inhibitors Use in Patients With Psoriasis

Proton Pump Inhibitors Use in Patients With Psoriasis

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02624544
Enrollment
0
Registered
2015-12-08
Start date
2016-01-31
Completion date
2016-12-31
Last updated
2022-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Detailed description

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis. The study will assess the evolution of skin lesions in psoriasis patients using PPIs

Interventions

DRUGdesonide

topical corticosteroid desonid 0,1% b.i.d

DRUGesomeprazole

esomex 40 mg twice daily

Sponsors

EMS
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnostic of Psoriasis

Exclusion criteria

* Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Efficacy - Change from baseline in skin lesions at 5 monthsBaseline - 5 monthsNumber of Participants With Treatment-Related Clinical Improvement of lesions Change From Baseline in skin lesions at 5 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026